MedPath

Smith Magenis Syndrome and Autism Spectrum Disorders

Not Applicable
Recruiting
Conditions
Smith-Magenis Syndrome
Autism Spectrum Disorder
Interventions
Other: Assessment
Registration Number
NCT05116904
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

Autism Spectrum Disorders (ASD) are a neurodevelopmental disorder. Their prevalence is estimated at around 0.4% of the general population worldwide. Their early onset and chronic nature make them a disabling disorder, all the more so as there is a high prevalence of sleep disorders in these populations, estimated at between 50 and 80%, with many complaints of insomnia in particular. These sleep disorders may result from biological, psychological, social, environmental and family factors.

Smith Magenis Syndrome (SMS) is a complex disorder characterized by severe neurological, psychological and behavioral disorders including sleep-wake rhythm disorders. It is a rare disease with a prevalence of 1/25 000.

These sleep disorders observed could be the consequence of a general dysregulation of the circadian system, since SMS patients show an inversion of the melatonin secretion profile (with a totally abnormal diurnal peak) and in patients with autism spectrum disorders, an overall reduction in melatonin secretion.

These sleep-wake disturbances cycle could play a significant role in learning deficits and in the frequency and severity of behavioral abnormalities observed in SMS and ASD.

In this project, investigators propose to study the mechanisms involved in the sleep-wake cycle disorders observed in Smith Magenis and Autism Spectrum children, in particular by evaluating the quality of the pupillary reflex using a pupillometer. The pupillary reflex is a simple and non-invasive method to test light sensitivity and the photobiological mechanisms involved.

In this way, investigators want to evaluate the diurnal profile of the pupillary reflex in children with Smith Magenis syndrome and with Autism Spectrum Disorders in relation to the diurnal melatonin profile.

Investigators will complete this study by determining the chronobiological profile of these patients by measuring different variables:

* Diurnal cortisol and amylase profile

* 24h body temperature and heart rate profile

* Urinary cortisol and 6-sulfatoxymelatonin (major metabolite of melatonin) profiles

* Daytime sleepiness profile measured subjectively by questionnaire and objectively via a waking EEG recording.

* Actimetry at home

* Polysomnography

* A neurocognitive and behavioural assessment

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Genetically confirmed Smith Magenis syndrome (microdeletion of the short arm of chromosome 17 or mutation of the RAI1 gene; obtained by FISH, CGH-array or molecular biology) and children with neuropsychologically confirmed autism spectrum disorder, with no genetic pathology found.
  • Aged 5-12 years
  • Consent form signed by the parent(s)
  • Requiring a sleep assessment in the Hopital Femme Mère Enfant paediatric sleep unit of Pr Franco
  • Affiliation to a social security system.
Read More
Exclusion Criteria
  • Associated ophthalmological disorders that do not allow the photomotor reflex to be studied: optic neuritis, glaucoma and retinitis pigmentosa.
  • Algic child (risk of measurement bias: when a patient is in pain his pupils dilate and we observe a greater amplitude in the photomotor reflex), defined by a score on the FPS-R Face Scale >4/10.

Only for SMS patients:

  • Dyschromatopsia detected in consultation with a rapid Ishihara test adapted to the child's cognitive level, if necessary supplemented by a test performed by ophthalmologists.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Children with Smith Magenis SyndromeAssessment-
Children with Autism Spectrum DisordersAssessment-
Primary Outcome Measures
NameTimeMethod
Measurement of salivary melatonin levelsOne day

This measurement will allow to evaluate the diurnal melatonin profile and will be evaluated using saliva samples.

This measurement will be done every 2 hours from 8am to 8pm, for one day

Measurement of the percentage change between pupil diameter at the end of light exposure and before exposureOne day

This measurement will allow to evaluate the diurnal profile of the pupillary reflex and will be measured by a NeuroLight pupillometer (IDMed).

This measurement will be done every 2 hours from 8am to 8pm, for one day

Secondary Outcome Measures
NameTimeMethod
Determination of the chronobiological profile : Sleep assessment by actimetry2 weeks

Home activity monitor during an outpatient recording with a watch in order to assess the sleep wake rhythm at home

Determination of the chronobiological profile :Sleep assessment by Polysomnography24 hours

Polysomnography during hospitalization in order to assess the structure of sleep

Neuropsychological assessmentOne day

WISC +/- Vineland

Determination of the chronobiological profile : Salivary cortisol levelsEvery 2 hours from 8am to 8pm, for one day

Salivary cortisol levels will be evaluated using saliva samples

Determination of the chronobiological profile : Amylase levelsEvery 2 hours from 8am to 8pm, for one day

Amylase levels will be evaluated using saliva samples

Determination of the chronobiological profile : Urinary 6-sulfatoxymelatonin levelover 24hours

Urinary 6-sulfatoxymelatonin level will be evaluated using urinary samples

Determination of the chronobiological profile : Urinary cortisol levelover 24hours

Urinary cortisol level will be evaluated using urinary samples

Determination of the chronobiological profile : Variations in body temperature in degreesover 24hours

Body temperature will be measured by ibuttonR placed on the surface of the skin

Determination of the chronobiological profile : Assessment of sleepiness by questionnaire (numerical score)Every 2 hours from 8am to 8pm, for one day

The Karolinska questionnaire will be carried out at the time of salivary sampling and pupil diameter measurement and the score obtained will be compared with the salivary melatonin level.

Determination of the chronobiological profile : Assessment of sleepiness by spectral analysis (EEG)Every 2 hours from 8am to 8pm, for one day

Somnolence will be evaluated by calculating power spectrum in several frequency bands.

Trial Locations

Locations (2)

Service Épilepsie-Sommeil-Explorations Fonctionnelles Neurologiques Pédiatriques Hôpital Femme-Mère-Enfant HCL

🇫🇷

Bron, France

GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Q19 Team (Centre National de la Recherche Scientifique & Lyon 1 Claude Bernard University)

🇫🇷

Bron, France

© Copyright 2025. All Rights Reserved by MedPath